DB
LXEO icon

Dmitry Balyasny’s Lexeo Therapeutics LXEO Stock Holding History

Dmitry Balyasny’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Buy
2,412,742
+823,157
+52% +$4.45M 0.01% 1005
2026
Q1 		$9.12M Sell
1,589,585
-45,441
-3% -$322K 0.01% 1076
2025
Q4 		$16.2M Sell
1,635,026
-2,278,762
-58% -$20.8M 0.02% 824
2025
Q3 		$26M Sell
3,913,788
-95,349
-2% -$461K 0.03% 600
2025
Q2 		$16.1M Buy
+4,009,137
New +$13.2M 0.02% 754

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Dmitry Balyasny's LXEO Position: Q2 2026 in Review

Dmitry Balyasny increased its Lexeo Therapeutics (LXEO) stake by 52% in Q2 2026, buying an estimated $4.45M and bringing the position to 2,412,742 shares worth $11.2M. The position accounts for 0.01% of the portfolio, ranked #1005.

Dmitry Balyasny first reported a position in LXEO in Q2 2025 and has held it in 5 quarters since. The position peaked at $26M in Q3 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Dmitry Balyasny held 2,412,742 shares of Lexeo Therapeutics worth $11.2M as of Q2 2026.
  • Dmitry Balyasny bought 823,157 Lexeo Therapeutics shares in Q2 2026, an estimated $4.45M.
  • Lexeo Therapeutics made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1005 holding.
  • Dmitry Balyasny first reported a position in Lexeo Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Dmitry Balyasny's Lexeo Therapeutics position peaked at $26M in Q3 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.